PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ACADIA Pharmaceuticals Inc. (ACAD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0042251084
CUSIP004225108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$3.09B
EPS-$0.37
PEG Ratio-0.42
Revenue (TTM)$726.44M
Gross Profit (TTM)$145.49M
EBITDA (TTM)-$67.83M
Year Range$17.71 - $33.99
Target Price$29.54
Short %8.76%
Short Ratio6.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACAD

ACADIA Pharmaceuticals Inc.

Popular comparisons: ACAD vs. ABT

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ACADIA Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


200.00%250.00%300.00%350.00%OctoberNovemberDecember2024FebruaryMarch
175.82%
356.36%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ACADIA Pharmaceuticals Inc. had a return of -40.98% year-to-date (YTD) and -6.67% in the last 12 months. Over the past 10 years, ACADIA Pharmaceuticals Inc. had an annualized return of -4.03%, while the S&P 500 had an annualized return of 10.61%, indicating that ACADIA Pharmaceuticals Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-40.98%7.28%
1 month-26.40%2.23%
6 months-25.24%14.98%
1 year-6.67%30.65%
5 years (annualized)-7.26%12.59%
10 years (annualized)-4.03%10.61%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-17.25%-10.30%
2023-7.59%-22.87%8.30%-1.28%40.53%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ACAD
ACADIA Pharmaceuticals Inc.
-0.11
^GSPC
S&P 500
2.64

Sharpe Ratio

The current ACADIA Pharmaceuticals Inc. Sharpe ratio is -0.11. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00OctoberNovemberDecember2024FebruaryMarch
-0.11
2.64
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ACADIA Pharmaceuticals Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-67.58%
-1.12%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ACADIA Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ACADIA Pharmaceuticals Inc. was 96.29%, occurring on Nov 12, 2010. Recovery took 645 trading sessions.

The current ACADIA Pharmaceuticals Inc. drawdown is 67.58%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.29%Mar 17, 20061175Nov 12, 2010645Jun 10, 20131820
-77.18%Jul 8, 2020493Jun 21, 2022
-73.99%Jul 20, 2015777Aug 17, 2018327Dec 5, 20191104
-40.8%Feb 28, 201432Apr 14, 2014161Dec 2, 2014193
-38.42%Dec 9, 201967Mar 16, 202029Apr 27, 202096

Volatility

Volatility Chart

The current ACADIA Pharmaceuticals Inc. volatility is 22.92%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%OctoberNovemberDecember2024FebruaryMarch
22.92%
3.36%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

726.44M726.44M517.24M484.15M441.76M

Cost Of Revenue

41.64M45.73M10.17M19.14M20.55M

Gross Profit

684.80M680.71M507.07M465.00M421.21M
Operating Expenses

Selling, General & Admin Expenses

406.56M406.56M369.09M396.03M388.66M

R&D Expenses

351.62M351.62M361.58M239.42M319.13M

Total Operating Expenses

758.18M754.09M730.67M635.44M707.79M
Income

Income Before Tax

-51.04M-51.04M-213.44M-167.52M-280.97M

Operating Income

-73.38M-73.38M-223.60M-170.44M-286.59M

EBIT

-77.29M-73.38M-223.60M-170.44M-286.59M

Earnings From Continuing Operations

-61.29M-61.29M-215.98M-167.87M-281.58M

Net Income

-61.29M-61.29M-215.98M-167.87M-281.58M

Income Tax Expense

10.25M10.25M2.53M351.00K611.00K

Interest Expense

-9.07M0.006.61M6.26M8.55M

Other Non-Operating Income (Expenses)

13.67M22.34M10.15M2.92M5.61M

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

0.000.000.000.000.00

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items